FDA cleared PRX-115’s IND for uncontrolled gout after a 30-day review, activating first Phase 2 sites following Phase 1 data showing single-dose urate levels below 6 mg/dL sustained up to 12 weeks. Protalix projects Elfabrio to capture 15-20% of a $3.4 billion Fabry market by 2030.